Innovative new therapies that correct the inherited genetic defect have enabled patients to achieve greater life expectancy. Further advances in nutritional and respiratory care allow patients to enjoy more active lifestyles. Hence these patients increasingly report symptoms of gastrointestinal dysmotility that include bloating, distension, flatulence and constipation. These symptoms are chronic, have no satisfactory treatment options, take precedence over respiratory symptoms and have a detrimental impact on Quality of Life.

There are approximately 70,000 patients with Cystic Fibrosis in Europe, 37,000 in the U.S. and 13,000 in Japan. About 80-90% of patients with Cystic Fibrosis experience symptoms of gastrointestinal dysmotility.